GT Biopharma, Inc. — Director's Dealing 2011

Jul 12, 2011

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: OXIS INTERNATIONAL INC (OXIS.OB)
CIK: 0000109657
Period of Report: 2011-06-30

Reporting Person: Saloff David (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Common Stock Option	$0.09	2021-06-30	Common Stock (777778)		Direct

Footnotes

F1: David Saloff received a non-qualified stock option to purchase up to 777,778 shares of Common Stock under the Issuer's 2010 Equity Incentive Plan. The options vest and become exercisable in equal quarterly installments during the one-year period following the date of grant. The options have a term of 10 years from the date of grant.